Salivary duct carcinoma is a rare but highly aggressive tumor of the salivary glands that has poor prognosis. There is no effective cure for this tumor. Peroxisome proliferator-activated receptor gamma (PPAR␥) is a member of the nuclear receptor family with diverse biological functions that include mediation of adipocyte differentiation, regulation of the monocyte-macrophage anti-inflammatory activity, and inhibition of tumor cell proliferation. Natural (prostaglandin J 2 , PG-J 2 ) and synthetic (thiazolinediones) PPAR␥ ligands with anti-proliferative agonist activity have been identified. The expression of PPAR␥ has been demonstrated in human colorectal, pancreas, breast, and prostate cancers but has never been explored in salivary duct carcinoma. The aim of our study was to investigate the expression patterns of PPAR␥ in salivary duct carcinoma, a finding that may provide a mechanism for treating patients with this highly aggressive tumor. Archival formalin-fixed tissues from 15 salivary duct carcinoma cases were analyzed for PPAR␥ expression by an immunohistochemical staining method using a monoclonal antibody against the PPAR␥. The tissue sections were subjected to antigen retrieval by a steam heat method. All the cases of salivary duct carcinoma originated from the parotid gland. Immunohistochemistry analyses showed positive expression of PPAR␥ in 12 (80%) cases, whereas 3 (20%) were negative. Of the positive cases, 9 (75%), 2 (17%) and 1 (8%) showed strong, moderate, and weak staining, respectively. All staining was cytoplasmic. Nuclear staining was not observed. We conclude that PPAR␥ is frequently (80%) expressed in salivary duct carcinoma, often at high levels, and is topographically located in the cytoplasm. The high-level expression of PPAR␥ may provide a potential molecular target for the treatment of salivary duct carcinoma using agonist ligands.
Salivary duct carcinoma, first described by Kleinsasser et al. (1) in 1968, is a rare tumor of the salivary glands that was officially recognized by the World Health Organization in 1991 as a distinct clinicopathologic entity (2) . Clinically, salivary duct carcinoma is characterized by its aggressive biologic behavior, and microscopically, it is characterized by resemblance to infiltrating ductal carcinoma of the breast (3). Many patients (Ͼ50%) with salivary duct carcinoma have lymph node metastases or show tumor extension into adjacent soft tissues at the time of presentation. The current main modality of treatment, surgical excision, has met with limited success, primarily because many tumors are at an advanced stage with early metastasis at the time of presentation and furthermore because the frequency of recurrence is high. An estimated 66% of patients with salivary duct carcinoma are dead within 4 years of diagnosis despite surgical resection (3) . The response rate to radiation treatment is very poor, and currently there is no effective chemotherapy for this tumor. It is therefore imperative for investigators to explore alternative therapy for salivary duct carcinoma.
Recent studies have shown high levels of androgen receptor expression in salivary duct carcinoma, raising the possibility of using hormonal treatment in the management of these patients (4, 5) . Patients with prostate carcinoma, which shows high frequency of androgen receptor expression, have been successfully managed by anti-androgen hormonal treatment (6) . However, clinical studies have yet to be carried out in salivary duct carcinoma to evaluate the efficacy of such treatment. Prompted by the finding of androgen receptor expression in salivary duct carcinoma, we sought to further explore the expression patterns, if any, of another nuclear hormone receptor, peroxisome proliferator-activated receptor ␥ (PPAR␥), in salivary duct carcinoma.
PPAR␥ is a member of the nuclear hormone receptor superfamily, which consists of a group of ligand-activated transcription factors that possess diverse biological functions (7, 8) . The molecular structure of PPAR␥ shows a central DNA-binding domain, an amino-terminal activation domain (AF-1), a carboxyl-terminal ligand-binding domain (LBD), and a ligand-dependent activation domain (AF-2) (9). PPAR␥ forms a heterodimeric DNAbinding complex with retinoid X receptor, and both (PPAR␥ and retinoid X receptor) can be independently or coactivated by specific natural or synthetic ligands, leading to regulation of specific transcription genes (9 -12) . The natural ligands for PPAR␥ that have been identified include the potent eicosanoid 15-deoxy-⌬ 12, 14 prostaglandin J 2 (15d-PG J 2 ), and linoleic acid, whereas synthetic ones include thiazolidinediones such as troglitazone, rosiglitazone, and pioglitazone. The thiazolidinedione ligands are currently used as oral insulin sensitizers and antihyperglycemic drugs in patients with non-insulindependent diabetes mellitus (9, (13) (14) (15) .
PPAR␥ is expressed in several tissues, including adipose tissue, where the gamma 2 isoform is preferentially expressed. In addition to the antidiabetic effect, ligand-activated PPAR␥ promotes adipogenesis and also regulates the monocyte-macrophage anti-inflammatory activity. Recent studies have also shown that PPAR␥ inhibits tumor cell proliferation and induces their terminal differentiation (16, 17) . Expression of PPAR␥ has been demonstrated in several cancers, including colorectal, pancreas, breast, and prostate carcinoma (16 -18) . However, to our knowledge, no studies have been carried out to evaluate PPAR␥ expression in salivary duct carcinoma.
In this study, we investigated and demonstrated by immunohistochemical staining the expression of PPAR␥ in salivary duct carcinoma. The expression of PPAR␥ in salivary duct carcinoma may provide a therapeutic target, in a fashion similar to the treatment of hormone receptor-expressing tumors such as prostate carcinoma (anti-androgen) and breast carcinoma (anti-estrogen, tamoxifen).
MATERIALS AND METHODS
The surgical pathology files of the University of Arkansas for Medical Sciences and the University of Pittsburgh Medical Center were searched for cases of salivary duct carcinoma. Fifteen cases with available microscopic slides and suitable paraffinembedded tissue blocks were identified for the period 1990 and 2000. Tissue from the resection tumor specimens, including portions of normal salivary gland, were fixed in 10% neutral buffered formalin, routinely processed, embedded in paraffin, sectioned at 5 m, and stained with hematoxylin and eosin. Fourteen patients were treated with parotidectomy with or without a neck dissection and/or radiation therapy. Only one patient was treated with radiation therapy alone. The clinical data and the histologic sections were reviewed to confirm the diagnosis.
Five-micrometer sections of formalin-fixed paraffin-embedded tissue were cut and prepared for IHC staining. The sections were incubated overnight at 4°C with a monoclonal antibody against human PPAR␥ (E-8; Santa Cruz Biotechnology, Santa Cruz, CA) at 1:50 dilution. A case of prostate carcinoma with known expression of PPAR␥ was used as positive control, whereas negative controls were generated by replacement of the primary antibody with a matched primary antibody of unrelated specificity. Before incubation with the primary antibody, all sections were subjected to antigen retrieval by the heat steam method and were endogenous peroxidase quenched with blocking solution (Zymed Laboratories, San Francisco, CA). The standard avidin-biotin-peroxidase technique was used using the Zymed Kit Detection system (Zymed Laboratories). The immunostaining was assessed semiquantitatively by two pathologists (PM and CYF), and the results were scored as follows: no staining being negative (Ϫ); Յ20% positive cells being weakly negative (ϩ); 30 to 40% positive cells being mildly positive (ϩϩ); 50 to 70% positive cells being moderately positive (ϩϩϩ); and Ͼ70% being intensely positive (ϩϩϩϩ). For the purposes of this study, the expression of PPAR␥ is considered strong if the staining is scored as ϩϩϩ or ϩϩϩϩ; ϩϩ and ϩ represent moderate and weak expression, respectively; and Ϯ or Ϫ indicate negative expression.
RESULTS
The clinical data and immunohistochemical staining results are summarized in Table 1 . The tumors studied were from 10 men and 5 women, with an age range of 36 to 86 years (mean ϭ 67.4 y). All of the 12 tumors arose from the parotid gland, and the majority of patients presented with Stage IV disease. The duration of symptoms ranged from 2 to 9 months, and all patients presented with a neck mass around the parotid area. The masses were painless in all but three patients, in whom the pain was associated with recent enlargement. Other symptoms seen at presentation included VIIth nerve palsy (2 patients), vocal cord paralysis (1 patient), and cervical lymph node enlargement (7 patients). Radical parotidectomy was performed on 14 patients, but all patients received radiation treatment. At the time of radical resection of the tumors, 10 patients were found to have lymph node metastases and/or adjacent soft tissue involvement. Subsequent follow-up of the 15 patients for Յ44 months (mean ϭ 20.2 mo) has shown that 5 died of their disease within 6 to 13 months, whereas 7 are alive with no evidence of disease and 3 patients have been lost to follow-up.
Pathologic Findings
On gross inspection of the resected specimens, the majority (12 of 15, 80%) of the tumors exhibited poor circumscription and showed extension into adjacent soft tissue. Cystic degeneration, necrotic foci, and hemorrhage were also seen in many tumors.
Microscopically, the tumors displayed the typical features, which have been described in salivary duct carcinoma (Fig. 1A) . The tumor growth pattern was characterized by infiltrating ductal and intraductal components, with the latter demonstrating a variety of patterns including solid, papillary, cystic, and cribriform (Fig. 1C) . The infiltrating ductal component showed small nests, cords, and single tumor cells embedded in dense desmoplastic collagenous stroma. Angiolymphatic and perineural invasion by tumor was present in many cases. In addition, foci of calcification were also noted. The individual tumor cells were predominantly characterized by nuclear enlargement, with hyperchromasia, prominent nucleoli, variably increased nuclear to cytoplasmic ratios, abundant amphophilic or eosinophilic cytoplasm, and frequent mitoses.
Immunohistochemical Detection of PPAR␥
The immunohistochemical staining of salivary duct carcinoma showed positive diffuse staining for PPAR␥ in the majority of cases (12 of 15, 80%), with 75% (9 of 12) of the cases showing strong staining (Fig. 1B) . Two (17%) and 1 (8%) of the cases demonstrated moderate and weak staining for PPAR␥. Only 3 (20%) of total cases studied were negative for PPAR␥ expression (Fig. 1C) . Of the positive cases, the staining pattern was uniform throughout the tissue section, with almost all neoplastic cells showing positive staining in the cytoplasm of most cases (with minimal or no nuclear staining). In two cases, the staining for PPAR␥ displayed a granular cytoplasmic pattern (Fig. 1C) . Cytoplasmic staining of the PPARs has been described before (19) . In addition, positive cytoplasmic staining in the striated and intercalated ducts of the normal salivary glands was also noted, whereas the acinar and stromal cells were negative, thus providing good internal control for the immunohistochemical staining (Fig. 2) .
Statistical Analysis
Statistical analysis, in our small series of salivary duct carcinoma, showed no correlation between the level of PPAR␥ expression and tumor stage (TNM and clinical), recurrence, or patient survival.
DISCUSSION
The current main treatment modality for salivary duct carcinoma is complete surgical excision fol- lowed by radiation therapy (4). However, salivary duct carcinoma frequently presents at an advanced stage (Stage IV for most patients in our study), therefore leading to treatment failure in most cases. Approximately 60% of the patients with salivary duct carcinoma die within 4 years of initial diagnosis (3, 4) . Currently, there is no effective chemotherapy for this malignancy, thus making the management of patients with distant metastases difficult. We observed in our study high levels of PPAR␥ expression in many salivary duct carcinoma, 12 of 15 (80%), and that expression was predominantly limited to the cytoplasm. Our interest in investigating the expression of PPAR␥ in salivary duct carcinoma arose from the observation that salivary duct carcinoma express androgen receptor, which is also a nuclear hormone receptor (4, 5) . In a previous study, androgen receptor expression was seen in Յ92% of salivary duct carcinoma, leading to speculation that hormonal treatment may have a role in the management of this tumor (4). Therapy targeted at hormone receptors has been successfully used in the treatment of prostate carcinoma (androgen ablation) and breast carcinoma (tamoxifen), both nuclear hormone receptor-expressing tumors. Salivary duct carcinoma shows some immunophenotypic similarity to prostate carcinoma, like prostate carcinoma and in addition to androgen receptor expression; it also expresses prostatespecific antigen and prostate acid phosphatase (20) . Salivary duct carcinoma bears microscopic resemblance to breast carcinoma, which itself shows spo- radic androgen receptor expression; and it is therefore not surprising that investigators have looked for estrogen and progesterone receptor expression in salivary duct carcinoma. However, estrogen and progesterone receptor expression in salivary duct carcinoma appears to be infrequent (5, 6, 21, 22) . Another notable finding was the demonstration of PPAR␥ expression in both prostate carcinoma and ductal carcinoma of the breast (23) (24) (25) . The expression of PPAR␥ in salivary duct carcinoma suggests that it may be possible to specifically target this receptor in the treatment of patients with this tumor.
The antiproliferative effect of PPAR␥ is mediated through the inhibition of the cyclin D1 gene. Wang et al. (9) demonstrated that when PPAR␥ is activated by 15d-PG J 2 , PGD 2 or by the synthetic ligand troglitazone, the result was inhibition of cyclin D1, blocking entry of the cell cycle into the S phase. This effect was not observed in cells that were deficient of PPAR␥ (26) . The antiproliferative effects of PPAR␥ ligands have been observed in breast, colon, and recently, in pancreatic carcinoma (18, 27) . In addition, PPAR␥ ligands also induce terminal differentiation in fibroblasts, human breast cancer, and liposarcoma cells. In the latter case, PPAR␥ ligands have been shown to arrest proliferation of liposarcoma cells and promote their maturation into adipocytes (16, 28, 29) .
A contradictory biologic effect was the observation in murine studies that troglitazone-activated PPAR␥ promoted tumorigenesis in the colon (27, 30 -32) . It is speculated that the apparent tumorigenic activity of PPAR␥ in the colon in these animals may be related to its anti-inflammatory effects, whereby a diminished inflammatory function may lead to a decrease in tumor surveillance (9, 31, 33) .
In our study, PPAR␥ expression was predominantly cytoplasmic. Shibuya et al. (34) demonstrated that nitration of PPAR␥ in macrophage cell lines (RAW 264), resulted in inhibition of the liganddependent translocation of PPAR␥ into the nucleus. Normally PPAR␥-ligand binding occurs in the cytosol, followed by translocation into the nucleus. Whether PPAR␥ in salivary duct carcinoma is nitrated or not or the translocation into the nucleus is precluded by a different mechanism remains unknown and requires further investigation.
Although PPAR␥ expression did not correlate with tumor stage, recurrence, or survival, its significance is that it provides a potential target site for therapeutic manipulation.
In summary, we have demonstrated a high level of expression of PPAR␥ in most salivary duct carcinoma. The diverse biologic functions of PPAR␥ and the mechanisms of specific ligand activation are complex and are yet to be fully understood. However, the expression of PPAR␥ in salivary duct carcinoma and other tumors offers a potential therapeutic target for developing drugs that specifically bind and activate this receptor to alter tumor growth.
